Cardiac Ion Channel Panel™ to Predict Torsades de Pointes Will be Assessed by Collaborative Industry Consortium

Share Article

The Drug Safety Executive Council and ChanTest Corporation Announce Technology Evaluation Consortium

The Drug Safety Executive Council (DSEC), an industry membership association run by Cambridge Healthtech Associates (CHA), and ChanTest Corporation, the industry leading provider of ion channel and GPCR drug discovery tools and solutions, today announced the latest project for DSEC’s Technology Evaluation Consortium.

The group will primarily evaluate ChanTest’s Cardiac Ion Channel Panel™, a drug screening platform using probabilistic models that have the potential to predict QT prolongation and the likelihood for developing Torsades de Pointes (TdP), which are considered critical risk factors for developing safe and effective new medications. Eight pharmaceutical companies, whose names are undisclosed, will participate in the venture.

“Accurate prediction of the potential for QT prolongation and more specifically the cardiac arrhythmia known as Torsades de Pointes are areas of serious concern for pharmaceutical companies involved in drug discovery and we are looking forward to working with ChanTest to further validate and qualify this exciting technology,” said Dr. Ernie Bush, Vice President Collaborative Projects at DSEC. “Our members place a high value on technologies that allow them to identify cardiac risks early in the drug development process, especially before the costly in vivo studies currently used to confirm this risk of TdP.”

“We believe that the Cardiac Ion Channel Panel and our probabilistic models will greatly improve the predictivity of QT prolongation and TdP. Our in vitro screens can be done quickly and inexpensively during early and subsequent phases of drug development,” said Buzz Brown, Founder, Executive Chairman and Chief Scientific Officer at ChanTest.

About Cambridge Healthtech Associates and the Drug Safety Executive Council
CHA is the leading organizer of consortia in life sciences. CHA reduces the costs of R&D by bringing companies together to work cooperatively. The Technology Evaluation Consortium determines the scientific utility of predictive safety technologies by leveraging the expertise of biopharmaceutical companies. CHA also manages DSEC, an online, peer membership of over 2,000 drug safety leaders. Learn more at and CHA is wholly-owned subsidiary of Cambridge Healthtech Institute (CHI).

About ChanTest Corporation (
ChanTest’s mission is to serve the research, drug discovery and drug development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the company has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and pre-clinical cardiac risk assessment service portfolio are the most comprehensive commercially available today. Because of ChanTest’s seminal role in the preclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past five years. ChanTest is based in Cleveland, Ohio. For more information, e-mail info(at)chantest(dot)com.

Drug Safety Executive Council (DSEC)
Contact: Alison Serrano
Tel: +1 (781) 972-5482
Email: aserrano(at)drugsafetycouncil(dot)org

Media: Reese A. Nank, APR
Reputations PR and Marketing
Tel: +1 (410) 218-9121
Email: reese(at)reputationspr(dot)com

Company: Mark Keck
ChanTest Corporation
Email: mkeck(at)chantest(dot)com


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Tracey Fielding
Cambridge Healthtech Institute
(781) 972-5429
Email >